The effect of antifibrotic drugs in rat precision-cut fibrotic liver slices

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Westra, Inge M ^a   Oosterhuis, Dorenda ^a   Groothuis, Geny M M ^a   Olinga, Peter ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANTIFIBROTIC AGENT; COLCHICINE; COLLAGEN TYPE 1; FIBRILLAR COLLAGEN; HEAT SHOCK PROTEIN 47; IMATINIB; PERINDOPRIL; PIRFENIDONE; PLATELET DERIVED GROWTH FACTOR; PROCOLLAGEN; ROSMARINIC ACID; SORAFENIB; SUNITINIB; TETRANDRINE; TRANSFORMING GROWTH FACTOR BETA; VALPROIC ACID; BIOLOGICAL MARKER;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT LIGATION; CONTROLLED STUDY; DRUG MECHANISM; EX VIVO STUDY; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; INCUBATION TIME; LIVER FIBROSIS; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LIVER CIRRHOSIS; METABOLISM; PATHOLOGY; PROCEDURES; STAINING; WISTAR RAT;

ANIMALS; BIOLOGICAL MARKERS; CELL SURVIVAL; COLCHICINE; COLLAGEN TYPE I; CYTOLOGICAL TECHNIQUES; GENE EXPRESSION REGULATION; LIVER CIRRHOSIS; MALE; PLATELET-DERIVED GROWTH FACTOR; RATS, WISTAR; STAINING AND LABELING; TRANSFORMING GROWTH FACTOR BETA;

EID: 84899680439     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095462     Document Type: Article

References (45)

1. Hernandez-Gea V, Friedman SL (2011) Pathogenesis of liver fibrosis. Annu Rev Pathol 6: 425-456.
2. Schuppan D, Afdhal NH (2008) Liver cirrhosis. Lancet 371: 838-851. (Pubitemid 351323895)
3. Friedman SL, Sheppard D, Duffield JS, Violette S (2013) Therapy for fibrotic diseases: Nearing the starting line. Sci Transl Med 5: 167sr1.
4. Friedman SL (2008) Mechanisms of hepatic fibrogenesis. Gastroenterology 134: 1655-1669.
5. Liu Y, Wen XM, Lui EL, Friedman SL, Cui W, et al. (2009) Therapeutic targeting of the PDGF and TGF-beta-signaling pathways in hepatic stellate cells by PTK787/ZK22258. Lab Invest 89: 1152-1160.
6. Schuppan D, Kim YO (2013) Evolving therapies for liver fibrosis. J Clin Invest 123: 1887-1901.
7. Andrae J, Gallini R, Betsholtz C (2008) Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22: 1276-1312. (Pubitemid 351717519)
8. Bonner JC (2004) Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 15: 255-273.
9. Dooley S, Ten Dijke P (2012) TGF-beta in progression of liver disease. Cell Tissue Res 347: 245-256.
10. Westra IM, Pham BT, Groothuis GM, Olinga P (2012) Evaluation of fibrosis in precision-cut tissue slices. Xenobiotica 43: 98-112.
11. de Graaf IA, Olinga P, de Jager MH, Merema MT, de Kanter R, et al. (2010) Preparation and incubation of precision-cut liver and intestinal slices for application in drug metabolism and toxicity studies. Nat Protoc 5: 1540-1551.
12. Olinga P, Schuppan D (2013) Precision-cut liver slices: A tool to model the liver ex vivo. J Hepatol 58: 1252-1253.
13. van de Bovenkamp M, Groothuis GM, Draaisma AL, Merema MT, Bezuijen JI, et al. (2005) Precision-cut liver slices as a new model to study toxicity-induced hepatic stellate cell activation in a physiologic milieu. Toxicol Sci 85: 632-638. (Pubitemid 40614292)
14. Westra IM, Oosterhuis D, Groothuis GMM, Olinga P (2014) Precision-cut liver slices as a model for the early onset of liver fibrosis to test anti-fibrotic drugs. Toxicol Appl Pharmacol 274: 328-338.
15. van de Bovenkamp M, Groothuis GMM, Meijer DKF, Olinga P (2006) Precision-cut fibrotic rat liver slices as a new model to test the effects of antifibrotic drugs in vitro. J Hepatol 45: 696-703. (Pubitemid 44466660)
16. Yoshiji H, Noguchi R, Kuriyama S, Ikenaka Y, Yoshii J, et al. (2005) Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. Am J Physiol Gastrointest Liver Physiol 288: G907-13. (Pubitemid 40563130)
17. Wang Y, Gao J, Zhang D, Zhang J, Ma J, et al. (2010) New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. J Hepatol.
18. Tugues S, Fernandez-Varo G, Munoz-Luque J, Ros J, Arroyo V, et al. (2007) Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 46: 1919-1926.
19. Yoshiji H, Kuriyama S, Noguchi R, Yoshii J, Ikenaka Y, et al. (2005) Combination of interferon-beta and angiotensin-converting enzyme inhibitor, perindopril, attenuates the murine liver fibrosis development. Liver International 25: 153-161. (Pubitemid 40298258)
20. Mannaerts I, Nuytten NR, Rogiers V, Vanderkerken K, van Grunsven LA, et al. (2010) Chronic administration of valproic acid inhibits activation of mouse hepatic stellate cells in vitro and in vivo. Hepatology 51: 603-614.
21. Li GS, Jiang WL, Tian JW, Qu GW, Zhu HB, et al. (2010) In vitro and in vivo antifibrotic effects of rosmarinic acid on experimental liver fibrosis. Phytomedicine 17: 282-288.
22. Di Sario A, Bendia E, Baroni G, Ridolfi F, Casini A, et al. (2002) Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production. J Hepatol 37: 584-591. (Pubitemid 35305537)
23. Garcia L, Hernandez I, Sandoval A, Salazar A, Garcia J, et al. (2002) Pirfenidone effectively reverses experimental liver fibrosis. J Hepatol 37: 797-805. (Pubitemid 35404219)
24. Hsu Y, Chiu Y, Cheng C, Wu C, Lin Y, et al. (2007) Antifibrotic effects of tetrandrine on hepatic stellate cells and rats with liver fibrosis. J Gastroen Hepatol 22: 99-111. (Pubitemid 44953424)
25. Lee SJ, Kim YG, Kang KW, Kim CW, Kim SG (2004) Effects of colchicine on liver functions of cirrhotic rats: Beneficial effects result from stellate cell inactivation and inhibition of TGF beta1 expression. Chem Biol Interact 147: 9-21. (Pubitemid 38076846)
26. Kountouras J, Billing BH, Scheuer PJ (1984) Prolonged bile duct obstruction: A new experimental model for cirrhosis in the rat. Br J Exp Pathol 65: 305-311. (Pubitemid 14085298)
27. Olinga P, Groothuis GMM (2001) Use of human tissue slices in drug targeting research. Drug Targeting: Organ-Specific Strategies 12: 309-331.
28. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193: 265-275.
29. Kinnman N, Francoz C, Barbu V, Wendum D, Rey C, et al. (2003) The myofibroblastic conversion of peribiliary fibrogenic cells distinct from hepatic stellate cells is stimulated by platelet-derived growth factor during liver fibrogenesis. Lab Invest 83: 163-173. (Pubitemid 36255362)
30. Neef M, Ledermann M, Saegesser H, Schneider V,Widmer N, et al. (2006) Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term. J Hepatol 44: 167-75. (Pubitemid 41772531)
31. Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, et al. (2009) Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 49: 1245-1256.
32. Hennenberg M, Trebicka J, Kohistani Z, Stark C, Nischalke HD, et al. (2010) Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis. Lab Invest.
33. Yoshiji H, Kuriyama S, Noguchi R, Ikenaka Y, Yoshii J, et al. (2006) Amelioration of liver fibrogenesis by dual inhibition of PDGF and TGF-beta with a combination of imatinib mesylate and ACE inhibitor in rats. Int J Mol Med 17: 899-904.
34. Yeki M, Koda M, Matono T, Sugihara T, Maeda K, et al. (2009) Preventative and therapeutic effects of perindopril on hepatic fibrosis induced by bile duct ligation in rats. Mol Med Report 2: 857-864.
35. Fisher R, Nau H, Gandolfi AJ, Brendel K (1991) Toxicity of valproic acid in liver slices from sprague-dawley rats and domestic pigs. Toxicol In Vitro 5: 201-205.
36. Ikura Y, Iwasa Y, Ueda M (2010) Valproic acid administration for hepatic fibrosis: A balance between antifibrotic efficacy and hepatotoxicity. Hepatology 51: 2227-8; author reply 2228.
37. Hsu Y, Chiu Y, Lee C, Wu C, Huang Y (2006) Anti-fibrotic effects of tetrandrine on bile-duct ligated rats. Can J Physiol Pharm 84: 967-976.
38. Park PH, Nan JX, Park EJ, Kang HC, Kim JY, et al. (2000) Effect of tetrandrine on experimental hepatic fibrosis induced by bile duct ligation and scission in rats. Pharmacol Toxicol 87: 261-268.
39. Salazar-Montes A, Ruiz-Corro L, Lopez-Reyes A, Castrejon-Gomez E, Armendariz-Borunda J (2008) Potent antioxidant role of pirfenidone in experimental cirrhosis. Eur J Pharmacol 595: 69-77.
40. Ehrlich HP, Bornstein P (1972) Microtubules in transcellular movement of procollagen. Nat New Biol 238: 257-260.
41. Poo JL, Feldmann G, Moreau A, Gaudin C, Lebrec D (1993) Early colchicine administration reduces hepatic fibrosis and portal hypertension in rats with bile duct ligation. J Hepatol 19: 90-94. (Pubitemid 23338016)
42. Castro V, Muriel P (1996) Comparative study of colchicine and trimethylcolchicinic acid on prolonged bile duct obstruction in the rat. J Appl Toxicol 16: 269-275. (Pubitemid 26228563)
43. Muriel P, Deheza R (2003) Fibrosis and glycogen stores depletion induced by prolonged biliary obstruction in the rat are ameliorated by metadoxine. Liver Int 23: 262-268. (Pubitemid 37265802)
44. Prockop DJ, Kivirikko KI (1995) Collagens: Molecular biology, diseases, and potentials for therapy. Annu Rev Biochem 64: 403-434.
45. Langrock T, Hoffmann R (2012) Analysis of hydroxyproline in collagen hydrolysates. Methods Mol Biol 828: 271-280.